We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

August 5, 2022

Five Expert Insights from the HealthXL Community

Commentary
HealthXL Team & HealthXL Community

Over the past month, our HealthXL community members discussed digital health evidence requirements, DTx label claims, and DTx - pharma collaborations, among other topics. We’ve put together a snapshot of five expert insights from these meetings.

#1 On Evidence Generation for Standalone DTx: Randomized Control Trials (RCTs) and Real-World Evidence (RWE) are the two main practices for evidence generation in DTx. While there is no clear answer on which format is more successful, some companies have seen success with a hybrid model. A hybrid design integrates the traditional RCT trial with design aspects to collect real-world data on patients. Traditional RCT’s are what physicians are most familiar with and thus trust, but they aren’t best suited to DTx. DTx solutions are constantly updating and improving. An 18-month RCT isn’t the best fit for an evolving solution. Hybrid models could be a way to both earn physician trust and allow for ongoing changes to digital solutions.  

#2 On evidence requirements from payers and regulatory bodies in oncology digital health: For payers in general, the return of investment will be measured through a cost savings lens or a member attraction and retention lens. FDA/regulatory approval for a digital health tool is not a strict requirement for payers. However, gathering sufficient evidence for partnerships with payers is proving difficult as they want a broader array of evidence than the FDA typically requires. Payers want real world evidence; they want to see the health economics impact and adherence data, which is costly and time consuming to gather, especially for small start ups. What does this say about the state of digital health if payers are more difficult to convince than the regulators?

#3 On DTx label claims: Label claims cannot be universal for one solution due to regulatory differences across regions. A digital solution could be regulated as a prescription digital therapeutic (PDT) in one region but a non-PDT in another region. Regulations control what claims labels can make about DTx solutions. Therefore, products may not have the same label claims everywhere. This makes it hard for companies to standardize commercialization strategies across countries, which could affect scalability.

#4 On Pharma - DTx collaborations: To maintain a strong relationship with pharma, DTx companies need to find numerous stakeholders to champion them throughout the partnership. It is important to focus on ROI, endpoints (both shared and individual), and stakeholders management. Keeping stakeholders onboard with a clear problem statement and roadmap is a key component of success.

#5 On employer partnerships for DTx in mental health: Working with employers requires a different approach than with life science or medical partners. While a strong evidence base is still vital, the focus will be more on productivity and employee satisfaction and less on healthcare outcomes. That said, clinical trials remain an important way to illustrate the efficacy of a solution. Although employers may not have the required expertise to dissect clinical evidence in detail, it is often a foot in the door. Helping employers to understand and navigate clinical evidence could create more opportunities for collaboration.

Want to join the conversation? Check here for upcoming meetings and events.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

No upcoming Virtual Events scheduled. Please check back again soon.

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

19th March 2024 @ 12pm ET

Emerging Trends: Decentralised to Home-based Clinical Trials

The landscape of cancer care is evolving, with startups changing the field by bringing care to patients' homes.

Hansa Bhargava
Featuring
Hansa Bhargava
Chief Clinical Strategy and Innovation Officer, Healio
20th March 2024 @ 12pm ET

Exploring Gen AI in the Pharmaceutical Industry

Gen AI in pharma is an emerging field that leverages AI to enhance various aspects of the pharmaceutical industry.

Dave Peak
Featuring
Dave Peak
Advisor, Independent
21st March 2024 @ 12pm ET

Unlocking AI's Potential in Medical Affairs

AI has significant potential to unlock new opportunities in medical affairs within the pharma industry.

Robert Stevens
Featuring
Robert Stevens
Principal, RS CONSULTATIVE, LLC
26th March 2024 @ 12pm ET

Managing Risks and Maximising ROI Strategies

Managing risks and maximising ROI is the new mantra of digital health investors.

Adam Kaufman
Featuring
Adam Kaufman
Senior Advisor, EVERSANA

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.